In a recent study, leveraging metadata from over 5870 breast cancer lesions, the authors showed that individuals with high germline epitope burden in ERBB2 were less likely to develop HER2 positive breast cancer compared to other subtypes. Here, ERBB2 is linked to breast cancer.